Chinese Clinical Oncology

• 综述与讲座 • Previous Articles     Next Articles

Progress in molecular targeted therapy for HER-2 positive inflammatory breast cancer

WANG Zexing,GUAN Xiaoxiang   

  1. Department of Oncology,Medical School of Nanjing University,Nanjing General Hospital of Nanjing Military Command,PLA,Nanjing 210002,China
  • Received:2012-08-17 Revised:2012-10-25 Online:2013-01-31 Published:2013-01-31
  • Contact: GUAN Xiaoxiang

Abstract: Human epidermal growth factor receptor-2(HER-2) positive inflammatory breast cancer is a very aggressive type of inflammatory breast cancer(IBC) with HER-2 over-expression or amplified. Clinically,such cancer is more aggressive and characterized by rapid local and systemic progression and overlying skin inflammation or discoloration without ulceration. With poor prognosis, but,combinations of neo-adjuvant systemic chemotherapy, surgery and radiation therapy,especially molecular targeted therapy can drastically alter the natural course of this disease. This article reviews the progress in molecular targeted therapy for HER-2 positive IBC in recent years.

No related articles found!
Viewed
Full text
284
HTML PDF
Just accepted Online first Issue Just accepted Online first Issue
0 0 0 0 0 284

  From Others local
  Times 9 275
  Rate 3% 97%

Abstract
98
Just accepted Online first Issue
0 0 98
  From Others
  Times 98
  Rate 100%

Cited

Web of Science  Crossref   ScienceDirect  Search for Citations in Google Scholar >>
 
This page requires you have already subscribed to WoS.
  Shared   
  Discussed   
No Suggested Reading articles found!